PFE - Novartis boasts Scemblix beats tyrosine kinase inhibitors for chronic myeloid leukemia
2024-05-31 12:19:46 ET
More on Novartis
- Novartis: Buy This Blue-Chip Dividend Stock On Sale Now
- Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results
- Novartis reports positive Phase 3 data for remibrutinib for chronic hives
- Novartis ending development of phase 3 KRAS lung cancer drug - report
- Novartis AG (NVS) Q1 2024 Earnings Call Transcript